Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05864976 · ClinicalTrials.gov registry record
Neurosurgical Neuronavigation Using Resting State MRI and Machine Learning
A clinical trial of Glioblastoma Multiforme, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT05864976 is a study of Glioblastoma Multiforme that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 100 participants, roughly in line with the 96-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT05864976, a study of Glioblastoma Multiforme, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is investigating the use of a computer algorithm to analyze scans of the brain before surgery to predict how a person's tumor will respond to treatment.
Conditions Studied
Interventions
- DEVICE Support Vector Machine
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-12-06 |
| Est. Completion | 2030-01-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05864976
The ClinicalTrials.gov registry entry for NCT05864976 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 96-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioblastoma Multiforme appearing as the primary indexed condition, and to 1 intervention - of which Support Vector Machine is the first listed.
NCT05864976 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT05864976 about?
NCT05864976 is a clinical study titled "Neurosurgical Neuronavigation Using Resting State MRI and Machine Learning". This study is investigating the use of a computer algorithm to analyze scans of the brain before surgery to predict how a person's tumor will respond to treatment.
What is the current status of trial NCT05864976?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2023-12-06. Estimated completion is 2030-01-31.
What conditions does trial NCT05864976 study?
This clinical trial studies the following conditions: Glioblastoma Multiforme.
What interventions are being tested in trial NCT05864976?
The interventions under investigation include: Support Vector Machine (DEVICE).
Who is sponsoring clinical trial NCT05864976?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05864976 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma Multiforme
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
RECRUITING · Phase 1
-
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
RECRUITING · Early Phase 1
-
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
RECRUITING · Phase 1
-
Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
RECRUITING · Phase 1
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.